The Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2009

Made: 25th November 2009

Coming into operation: 23rd December 2009

In accordance with section 31(3) of that Act, it has consulted with the Advisory Council on the Misuse of Drugs.

Citation and Commencement

1

These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2009 and shall come into operation on 23rd December 2009.

Interpretation

2

• (1) In these Regulations, “the 2002 Regulations” means the Misuse of Drugs Regulations (Northern Ireland) 2002[^f00003]

• (2) The Interpretation Act (Northern Ireland) 1954[^f00004] shall apply to these Regulations as it applies to an Act of the Assembly.

Amendments to the 2002 Regulations

3

The 2002 Regulations shall be amended as follows.

4

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5

• (1) In Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

• (a) in paragraph 1(a)—

• (i) after “Concentrate of poppy-straw”, insert—

[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1,2,3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone 3–Dimethylheptyl–11–hydroxyhexahydrocannabinol

• (ii) after “Fungus (of any kind) which contains psilocin or an ester of psilocin”[^f00006], insert—

[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol

• (b) after paragraph 1(f), insert—

(g) 1–benzylpiperazine or any compound (not being a compound for the time being specified in Schedule 4) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways— (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups; (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups; (h) any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (i) any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (j) any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent; (k) any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent; (l) any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.

• (2) In paragraph 1 of Schedule 2 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27)—

• (a) after “Myrophine”, insert “Nabilone”;

• (b) after “Norpipanone”, insert “Oripavine”.

• (3) In paragraph 1 of Part 1 of Schedule 4 (which specifies controlled drugs subject to the requirements of regulations 22, 23, 26 and 27), after “Chlordiazepoxide”, insert—

1–(3–chlorophenyl)piperazine 1–(3–chlorophenyl)–4–(3–chloropropyl)piperazine

• (4) In Part 2 of Schedule 4 (controlled drugs excepted from the prohibition on possession when in the form of a medicinal product)—

• (a) in paragraph 1—

• (i) before “4–Androstene–3,17–dione”[^f00007], insert—

5α–Androstane–3,17–diol Androst-4-ene-3,17-diol 1–Androstenediol 1–Androstenedione

• (ii) after “4–Androstene–3,17–dione”, insert “5–Androstenedione”;

• (iii) after “Boldenone”, insert “Boldione”;

• (iv) after “Clostebol”, insert—

Danazol Desoxymethyltestosterone

• (v) after “Furazabol”, insert—

Gestrinone 3–Hydroxy–5α–androstan–17–one

• (vi) after “Nandrolone”, insert “19–Norandrostenedione”;

• (vii) after “19–Nor–5–Androstene–3,17–diol”[^f00008], insert “19–Norandrosterone”;

• (viii) after “Norethandrolone”, insert “19–Noretiocholanolone”;

• (ix) after “Propetandrol”, insert “Prostanozol”;

• (x) after “Testosterone”, insert “Tetrahydrogestrinone”;

• (b) in paragraph 4, after “Somatropin”, insert—

Zeranol Zilpaterol

Signed

Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 25th November 2009

Norman Morrow — A Senior Officer of the Department of Health, Social Services and Public Safety

Explanatory note

(This note is not part of the Regulations)

EXPLANATORY NOTE

These Regulations insert 1–benzylpiperazine (BZP), all but two of a group of substituted piperazines and the synthetic cannabinoid agonists into Schedule 1 to the Misuse of Drugs Regulations (Northern Ireland) 2002 (“the 2002 Regulations”), save for Nabilone which is inserted into Schedule 2 to the 2002 Regulations along with Oripavine. The two other substituted piperazines are inserted into Part 1 of Schedule 4 to the 2002 Regulations and 15 anabolic steroids and 2 non-steroidal agents are inserted into Part 2 of that Schedule. The schedule in which a controlled drug is placed primarily affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to those drugs.

Gamma–butyrolactone (GBL) and 1, 4–butanediol (1, 4–BD) are not inserted into any schedule. However, regulation 4 makes it lawful to import, export, produce, supply, offer to supply or possess these substances except where a person does so, knowing or believing that it will be used for the purpose of human ingestion.

Footnotes

[^f00001]: 1971 c.38 Section 22 of that Act was amended by section 177(1) of, and paragraph 12 of Schedule 4 to, the Customs and Excise Management Act 1979(c.2)

[^f00002]: S.R. & O.(N.I) 1973 No 504; Article 5(a) and S.I.1999 No 283(N.I.1), Article 3(6)

[^f00003]: S.R.2002 No 1; the relevant amending Regulations are S.R.2003 No. 314,324 and 420, S.R.2005 No. 119,360 and 564, S.R.2006 No. 44, 214, 264 and 334, and S.R.2007 No 348.

[^f00004]: 1954 c.33 (N.I)

[^f00007]: “4-Androstene-3, 17-Dione” was inserted into S.R.2002 No 1 by S.R.2003 No 314

[^f00008]: “19-Nor-5-Androstene-3, 17-diol” was inserted into S.R.2002 No 1 by S.R.2003 No.314

Editorial notes

[^key-f5069726027e2e01359a04443292ead6]: Reg. 1 in operation at 23.12.2009, see reg. 1

[^key-d0d9afbd7d95f8b461d9348acc7afe93]: Reg. 2 in operation at 23.12.2009, see reg. 1

[^key-33eb7ecf14be07a314de771ac8168c35]: Reg. 3 in operation at 23.12.2009, see reg. 1

[^key-3ba41ed7906827a5054255d9be37a523]: Reg. 5 in operation at 23.12.2009, see reg. 1

[^key-5bbffda1ca6fe8c670d7b52050448bf2]: Reg. 4 revoked (23.12.2009) by The Misuse of Drugs (Amendment) (No.2) Regulations (Northern Ireland) 2009 (S.R. 2009/397), regs. 1, 4